Advertisement
Table 1 Demographic, cognitive and pathological characteristicsa of MAP participants included in the present study
| Variable | All participants (n = 150) | NCI (n = 51) | MCI (n = 42) | Dementia (n = 57) |
|---|---|---|---|---|
| Demographic | ||||
| Female, no. (%) | 105 (70%) | 40 (78%) | 27 (64%) | 38 (67%) |
| Age at death, years | 88.7 ± 6.3 | 86.7 ± 6.7 | 88.1 ± 6.8 | 90.9 ± 4.7 |
| Education, years | 14.6 ± 2.9 | 13.9 ± 2.5 | 15.0 ± 2.8 | 15.0 ± 3.3 |
| Race, no. W:AA | 146:4 | 49:2 | 41:1 | 56:1 |
| APOE ε4 carrier, no. (%) | 33 (22%) | 7 (14%) | 11 (26%) | 15 (26%) |
| PMI, hours | 6.6 ± 3.8 | 6.2 ± 2.1 | 7.6 ± 5.6 | 6.2 ± 3.1 |
| Cognitive function proximate to death | ||||
| Global cognition score | −0.77 ± 1.01 | 0.10 ± 0.39 | −0.47 ± 0.43 | −1.80 ± 0.78 |
| MMSE | 21.9 ± 8.2 | 27.7 ± 1.9 | 24.9 ± 4.6 | 14.4 ± 8.1 |
| Pathological | ||||
| Macroinfarcts, no (%)b | 45 (30%) | 10 (20%) | 15 (36%) | 20 (35%) |
| Lewy bodies, no (%)b | 25 (17%) | 4 (8%) | 1 (2%) | 20 (35%) |
| Hippocampal sclerosis, no (%)b | 14 (9%) | 0 (0%) | 4 (10%) | 10 (18%) |
| Arteriolosclerosisb | 1.39 ± 0.87 | 1.24 ± 0.84 | 1.38 ± 0.82 | 1.53 ± 0.93 |
| Amyloid plaquesc | 5.3 ± 5.9 | 2.9 ± 3.3 | 5.5 ± 6.5 | 7.3 ± 6.5 |
| Tanglesc | 1.1 ± 3.0 | 0.4 ± 1.7 | 1.1 ± 3.0 | 1.8 ± 3.7 |
